Surgical salvage was found to be associated with improved OS for patients with recurrent locoregional and distant metastatic OPSCC, independent of HPV tumor status.
READ FULL ARTICLE
From Wiley Online Library
Improved overall survival (OS) was found to be associated with surgical salvage in patients with recurrent locoregional and distant metastatic oropharyngeal squamous cell carcinoma (OPSCC), independent of human papillomavirus (HPV) tumor status, according to an article published online in the journal Cancer.
Participants in the study included patients with recurrent OPSCC from two institutions from 2000 to 2012. Immunohistochemistry and/or in situ hybridization were used to evaluate the status of each patient’s tumor. Kaplan-Meier and Cox proportional hazards methods were used to evaluate OS.
The majority of patients (80 out of 108) were HPV-positive, 65 of the patients had locoregional metastatic first recurrences and 43 had distant metastatic first recurrences. HPV-positive tumor status was found to be related to a longer time to disease recurrence (P<0.01). Several factors have an independent association with OS after disease recurrence: HPV-positive tumor status (aHR = 0.23; 95% CI: 0.09, 0.58;P=0.002), longer time to disease recurrence (≥1 year; aHR = 0.36; 95% CI: 0.18, 0.74; P=0.006), and surgical salvage (aHR = 0.26; 95% CI: 0.12, 0.61; P=0.002). Furthermore, researchers found an independent association between surgical salvage and improved OS compared with nonsurgical treatment among patients with both locoregional (aHR = 0.15; 95% CI: 0.04, 0.56; P=0.005) and distant (aHR = 0.19; 95% CI: 0.05, 0.75; P=0.018) metastatic disease recurrences.
The study suggests that further data be obtained to confirm the impact of surgical salvage on OS among patients with distant metastases.
Surgical salvage was found to be associated with improved OS for patients with recurrent locoregional and distant metastatic OPSCC, independent of HPV tumor status.
READ FULL ARTICLE
From Wiley Online Library
You’ve read {{metering-count}} of {{metering-total}} articles this month.
We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.
{{login-button}} {{register-button}}
Want to view more content from Cancer Therapy Advisor?
Register now at no charge to access unlimited clinical news, full-length features, case studies, conference coverage, and more.
{{login-button}} {{register-button}}
Please login or register first to view this content.